[go: up one dir, main page]

AR029322A1 - Un polinucleotido de estreptococo aislado que codifica un polipeptido capaz de generar anticuerpos que tienen especificidad de union para un segundo polipeptido de secuencias reveladas, los polipeptidos mencionados y un proceso para su fabricacion, un polipeptido quimerico, compuesto por dichos segu - Google Patents

Un polinucleotido de estreptococo aislado que codifica un polipeptido capaz de generar anticuerpos que tienen especificidad de union para un segundo polipeptido de secuencias reveladas, los polipeptidos mencionados y un proceso para su fabricacion, un polipeptido quimerico, compuesto por dichos segu

Info

Publication number
AR029322A1
AR029322A1 ARP990106746A ARP990106746A AR029322A1 AR 029322 A1 AR029322 A1 AR 029322A1 AR P990106746 A ARP990106746 A AR P990106746A AR P990106746 A ARP990106746 A AR P990106746A AR 029322 A1 AR029322 A1 AR 029322A1
Authority
AR
Argentina
Prior art keywords
polypeptide
generating antibodies
isolated
streptococo
polinucleotide
Prior art date
Application number
ARP990106746A
Other languages
English (en)
Inventor
Josee Hamel
Clement Rioux
Denis Martin
Bernard R Brodeur
Isabelle Pineau
Nathalie Charland
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR029322(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of AR029322A1 publication Critical patent/AR029322A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se refiere a un polinucleotido de estreptococo aislado que codifica un polipéptido capaz de generar anticuerpos que tienen especificidad de union para un segundo polipéptido. Provee 1) el polinucleotido que codifica el polipéptido, 2) el polipéptido capaz de generar dichos anticuerpos y 3) el segundo polipéptido cuyas secuencias características se revelan. También son objeto de la invencion un vector que comprende dicho polinucleotido, una célula hospedadora transferasa con dicho vector, y un proceso para producir dicho polipéptido capáz de generar anticuerpos que tienen especificidad de union para el segundo polipéptido. Finalmente se proveen polipéptidos quiméricos que comprenden dos o más de dichos segundos polipéptidos. Los polinucleotidos y polipéptidos pueden utilizarse para la preparacion de vacunas para el tratamiento terapéutico o profiláctico de la meningitis, la otitis media, bacteriemia, infeccion neumonica o la infeccion bacteriana estreptococica. Comprende también las vacunas y su método de preparacion.
ARP990106746A 1998-12-23 1999-12-23 Un polinucleotido de estreptococo aislado que codifica un polipeptido capaz de generar anticuerpos que tienen especificidad de union para un segundo polipeptido de secuencias reveladas, los polipeptidos mencionados y un proceso para su fabricacion, un polipeptido quimerico, compuesto por dichos segu AR029322A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23

Publications (1)

Publication Number Publication Date
AR029322A1 true AR029322A1 (es) 2003-06-25

Family

ID=22351610

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106746A AR029322A1 (es) 1998-12-23 1999-12-23 Un polinucleotido de estreptococo aislado que codifica un polipeptido capaz de generar anticuerpos que tienen especificidad de union para un segundo polipeptido de secuencias reveladas, los polipeptidos mencionados y un proceso para su fabricacion, un polipeptido quimerico, compuesto por dichos segu

Country Status (29)

Country Link
EP (2) EP2261358B1 (es)
JP (2) JP4761623B2 (es)
KR (4) KR101078919B1 (es)
CN (3) CN101134775A (es)
AP (1) AP2001002199A0 (es)
AR (1) AR029322A1 (es)
AT (1) ATE394489T1 (es)
AU (1) AU1764900A (es)
BR (1) BR9916477A (es)
CA (1) CA2356836C (es)
CL (1) CL2009002037A1 (es)
CY (3) CY1108223T1 (es)
CZ (2) CZ302790B6 (es)
DE (1) DE69938670D1 (es)
DK (3) DK1950302T3 (es)
EA (1) EA007409B1 (es)
ES (3) ES2400280T3 (es)
HU (1) HU229664B1 (es)
IL (3) IL143905A0 (es)
MX (1) MXPA01006427A (es)
NO (1) NO330800B1 (es)
NZ (1) NZ512574A (es)
OA (1) OA11736A (es)
PL (3) PL206576B1 (es)
PT (3) PT2261358E (es)
TR (2) TR200200633T2 (es)
UY (1) UY25877A1 (es)
WO (1) WO2000039299A2 (es)
ZA (1) ZA200105114B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347600T1 (de) 1998-02-20 2006-12-15 Id Biomedical Corp Gruppe b-streptococcus antigene
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
AU1764900A (en) * 1998-12-23 2000-07-31 Id Biomedical Corporation Novel streptococcus antigens
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
WO2001096379A2 (en) 2000-06-12 2001-12-20 University Of Saskatchewan Immunization of dairy cattle with chimeric gapc protein against streptococcus infection
NZ553554A (en) 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
WO2002079475A2 (en) * 2001-03-30 2002-10-10 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
AU2002317107B2 (en) 2001-07-06 2008-06-12 Id Biomedical Corporation Group B streptococcus antigens and corresponding DNA fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
EP1456231A2 (en) * 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
SI1601770T1 (sl) * 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
EP1615950A2 (en) * 2003-04-15 2006-01-18 Intercell AG S. pneumoniae antigens
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
CA2694466A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
MX2010011412A (es) * 2008-04-16 2010-11-12 Glaxosmithkline Biolog Sa Vacuna.
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
CN102413838A (zh) 2009-04-30 2012-04-11 科勒制药集团有限公司 肺炎球菌疫苗及其用途
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
AU2011336366B2 (en) 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
AU2012207088A1 (en) 2011-01-20 2013-05-02 Children's Medical Center Corporation Vaccines and compositions against Streptococcus pneumoniae
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
AU2013207191B2 (en) * 2012-01-05 2017-10-26 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers
KR20150093838A (ko) * 2012-12-14 2015-08-18 사노피 파스퇴르 리미티드 면역원성을 평가하기 위한 방법
ES2883343T3 (es) 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
DK3096786T3 (da) 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SG11201604728XA (en) 2014-01-21 2016-08-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10668164B2 (en) 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
MX395525B (es) 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
BR112018000087A2 (pt) 2015-07-21 2018-09-04 Pfizer Inc. composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN114728050A (zh) 2019-07-31 2022-07-08 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
CN114667343A (zh) 2019-11-01 2022-06-24 辉瑞大药厂 大肠杆菌组合物及其方法
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CN115605498A (zh) 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20240128715A (ko) 2022-01-13 2024-08-26 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN119317445A (zh) 2022-05-11 2025-01-14 辉瑞公司 用于生产含有防腐剂的疫苗制剂的方法
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
CN120265317A (zh) 2022-11-22 2025-07-04 辉瑞公司 包含经缀合的荚膜糖抗原的免疫原性组合物及其用途
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121263203A (zh) 2023-05-19 2026-01-02 葛兰素史克生物有限公司 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DE69432658T2 (de) * 1993-03-19 2004-04-08 Gunnar Lindahl Rib-protein, ein oberflächenprotein welches immunität gegen viele streptococcus-stämme der gruppe b verleiht, reinigungsverfahren für das rib-protein, testsatz und pharmazeutische zusammenstellung (arznei)
AU700080B2 (en) * 1995-06-07 1998-12-17 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the HSP70 family
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US6420135B1 (en) * 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
KR20010024299A (ko) * 1997-09-24 2001-03-26 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 사람 보체 ｃ3 분해단백질분해효소
WO1999053940A1 (en) * 1998-04-23 1999-10-28 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
CN1318103A (zh) * 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
EP2053126A1 (en) * 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
IL142017A0 (en) * 1998-09-24 2002-03-10 Univ Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
EP1140157B1 (en) * 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
AU1764900A (en) * 1998-12-23 2000-07-31 Id Biomedical Corporation Novel streptococcus antigens

Also Published As

Publication number Publication date
JP2010142246A (ja) 2010-07-01
HK1118575A1 (en) 2009-02-13
TR200102497T2 (tr) 2002-01-21
EP2261358A3 (en) 2011-02-23
CY1114722T1 (el) 2016-10-05
AU1764900A (en) 2000-07-31
EP2261358B1 (en) 2014-05-14
HU229664B1 (en) 2014-04-28
CZ303675B6 (cs) 2013-02-27
CA2356836A1 (en) 2000-07-06
CN1332803A (zh) 2002-01-23
CZ302790B6 (cs) 2011-11-09
MXPA01006427A (es) 2002-06-04
ES2400280T3 (es) 2013-04-08
CN1654657A (zh) 2005-08-17
DE69938670D1 (de) 2008-06-19
IL194230A (en) 2013-12-31
ES2306528T3 (es) 2008-11-01
HUP0104774A2 (hu) 2002-04-29
NZ512574A (en) 2004-03-26
PT1950302E (pt) 2013-01-16
AP2001002199A0 (en) 2001-09-30
KR101170203B1 (ko) 2012-07-31
PT2261358E (pt) 2014-07-30
CN101134775A (zh) 2008-03-05
KR100802198B1 (ko) 2008-02-11
OA11736A (en) 2005-06-12
CN100398653C (zh) 2008-07-02
WO2000039299A2 (en) 2000-07-06
KR20060134227A (ko) 2006-12-27
UY25877A1 (es) 2000-08-21
CZ20012161A3 (cs) 2001-10-17
EP1141306B1 (en) 2008-05-07
CY1108223T1 (el) 2014-02-12
ES2480417T3 (es) 2014-07-28
PL206576B1 (pl) 2010-08-31
TR200200633T2 (tr) 2002-06-21
CA2356836C (en) 2011-09-13
WO2000039299A3 (en) 2000-11-02
JP5039802B2 (ja) 2012-10-03
NO330800B1 (no) 2011-07-18
DK1950302T3 (da) 2013-01-14
EA200100565A1 (ru) 2002-04-25
PL204073B1 (pl) 2009-12-31
DK2261358T3 (da) 2014-07-28
JP2002533123A (ja) 2002-10-08
KR20080036666A (ko) 2008-04-28
ZA200105114B (en) 2002-11-21
IL194230A0 (en) 2011-08-01
KR20010104693A (ko) 2001-11-26
PT1141306E (pt) 2008-07-30
KR20100063814A (ko) 2010-06-11
IL143905A0 (en) 2002-04-21
NO20013045D0 (no) 2001-06-19
EP2261358A2 (en) 2010-12-15
NO20013045L (no) 2001-08-20
BR9916477A (pt) 2004-06-22
IL143905A (en) 2011-05-31
KR101078919B1 (ko) 2011-11-01
JP4761623B2 (ja) 2011-08-31
EP1141306A2 (en) 2001-10-10
PL205041B1 (pl) 2010-03-31
CY1115340T1 (el) 2017-01-04
ATE394489T1 (de) 2008-05-15
CL2009002037A1 (es) 2010-06-25
PL349777A1 (en) 2002-09-09
CN1191362C (zh) 2005-03-02
KR100891398B1 (ko) 2009-04-02
HUP0104774A3 (en) 2007-10-29
EA007409B1 (ru) 2006-10-27
DK1141306T3 (da) 2008-08-18

Similar Documents

Publication Publication Date Title
AR029322A1 (es) Un polinucleotido de estreptococo aislado que codifica un polipeptido capaz de generar anticuerpos que tienen especificidad de union para un segundo polipeptido de secuencias reveladas, los polipeptidos mencionados y un proceso para su fabricacion, un polipeptido quimerico, compuesto por dichos segu
NO331103B1 (no) Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende dette
BR0208944A (pt) quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos
ATE120487T1 (de) Therapeutische zusammensetzungen gegen streptokokken-infektionen, transformierte wirte, verfahren zur immunisierung und gentechnologisch hergestellte produkte.
DE69635783D1 (de) Antigen omp26 aus haemophilus influenzae
ES2068907T3 (es) Secuencias de nucleotidos que codifican una proteina con actividad ureasica.
AR003124A1 (es) Proteinas estreptococicas de shock termico miembros de la familia de hsp7270,secuencia de adn que codifica para dichos polipeptidos, vector deexpresion, molecula de adn recombinante, metodo para producir un polipeptido o fragmento del mismo, anticuerpo o fragmento del mismo y anticuerpo monoclonal,
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
NO20070618L (no) Forbindelser og fremgangsmater for immunterapi og diagnose av tuberkulose.
AU2001276619A1 (en) Immunisation against chlamydia pneumoniae
HUP0102304A1 (hu) B Csoportba tartozó Streptococcus antigének
HUP0102639A1 (hu) A MAGE-család tumorral összefüggő antigénszármazékai és azokat kódoló nukleinsavszekvenciák, továbbá ezek alkalmazása vakcinázásra használható fúziós fehérjék és készítmények előállításában
DE69032408D1 (de) Kreuzschützende salmonella impfstoffe
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
BR0108654A (pt) Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo
DE60118359D1 (de) Humanische pellino-polypeptide
NO20025146L (no) Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav
BR9908476A (pt) Peptìdeo, composição terapêutica, e, processo para conferir imunidade protetora a um paciente, contra a infecção de s. pneumoniae
DE60126490D1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
NZ515912A (en) Fimbrial proteins
ATE166880T1 (de) Impfstoff gegen cholera
SE0101030D0 (sv) Immunogenic cell surface proteins of helicobacter pylori
ATE341613T1 (de) Fluordesoxyuridin-resistente streptococcus gordonii stämme
SE9901548D0 (sv) Helicobacter pylori antigens

Legal Events

Date Code Title Description
FC Refusal